Biodesix, Inc.
BDSXHealthcareNASDAQDiagnostics & Research · Last scanned Oct 24, 2026
Scan Results
Daily timeframeBiodesix, Inc. operates as a diagnostic solutions company. Valued at $223.5M, BDSX is a micro-cap name in its sector. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
Market Cap
$223.5M
Beta
0.55
P/E (TTM)
—
P/E (Fwd)
-96.27
EPS (TTM)
$-3.10
EPS (Fwd)
$-0.22
ROE
-540.0%
ROA
-14.1%
Cash
$30.0M
Total Debt
$71.8M
Free CF
-$10.9M
52W Change
214.7%
Annual Financials
Cash vs Debt
Where BDSX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BDSX finished 17.00% above its 150-day moving average ($20.00) and 30.36% above its 200-day moving average ($17.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDSX overbought or oversold?
At the October 20, 2026 close, BDSX's RSI(14) was 27.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $30.0M in cash, though total debt stands at $71.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$10.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -540.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $38.2M (2022) to $88.5M (2025), reflecting a 132% increase over the period.
BDSX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Biodesix, Inc. and its sector.